Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. // The Lancet Neurology. – URL: https://www.sciencedirect.com/science/article/pii/S1474442226002772?dgcid=rss_sd_all
Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology. https://www.sciencedirect.com/science/article/pii/S1474442226002772?dgcid=rss_sd_all
“Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.” The Lancet Neurology.
@article{article68882,
title = {Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial},
journal = {The Lancet Neurology},
url = {https://www.sciencedirect.com/science/article/pii/S1474442226002772?dgcid=rss_sd_all}
}